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Slow reacting substance (SRS) x was first discovered by Feldberg and Kellaway (1) 
in the perfusate of a guinea pig lung treated with cobra venom. This material, which 
caused a characteristic contraction of selected smooth muscle preparations, was later 
found in the perfusates of sensitized guinea pig or human lungs after treatment with 
antigen  (2,  3).  Because of its physiological  effects and  immunologic origin,  it  was 
thought that SRS could play an important role as a mediator of immediate hypersen- 
sitivity  reactions,  and  immunologically  generated  SRS  was  named  slow  reacting 
substance of anaphylaxis (SRS-A). 
For many years, progress on the study of SRS-A was hampered by the very small 
quantities  available.  Recently,  however,  the  use  of calcium  ionophore  A  23187- 
stimulated mouse mastocytoma cells (4,  5)  or rat basophilic leukemia cells (6,  7)  has 
led  to  the  generation  of SRS  in  sufficient  quantity  to  allow  for  their  chemical 
characterization. These SRS were identified as metabolites of arachidonic acid (20:4) 
and named leukotrienes C  and D  (LTC and LTD).  LTC, originally obtained  from 
mouse  mastocytoma cells  is  5-hydroxy-6-S-),-glutamylcysteinylglycyl-7,9,11,14-eico- 
satetraenoic acid, an adduct of arachidonic acid and glutathione  (5).  LTD, the SRS 
produced by rat basophilic leukemia cells, is 5-hydroxy-6-S-cysteinylglycyl-7,9,11,14- 
eicosatetraenoic acid (6,  7). It is believed that LTD has the properties of the SRS-A 
obtained from antigenically challenged guinea pig or human lung (6, 8). 
In a recent paper (9), we reported that mouse peritoneal macrophages release SRS 
in  response to a  phagocytic challenge with  unopsonized  zymosan. This compound, 
known to be a metabolite of 20:4, was purified by solvent extraction, Sephadex G-25 
column  chromatography,  and  reverse-phase high  pressure  liquid  chromatography 
(HPLC). Chemical characterization of the purified SRS indicated structural features, 
all of which were consistent with the identity of the compound as a  20:4 metabolite 
that  contained  glutathione,  although  characterization  of the  20:4  portion  of the 
molecule has not yet been completed. In this paper, we present a simple radiochemical 
method  for  the  assay  of the  release  of this  SRS  (which  we  designate  LTC)  by 
macrophages in vitro. Using this assay, we provide data that establish the relationship 
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of LTC  production  to  the  process  of phagocytosis  and  the  release  of other  20:4 
metabolites by the cells. 
Materials and Methods 
Macrophage Cultures.  Primary cultures of peritoneal macrophages  were  established  from 
resident cells of female Swiss Webster mice (Taconic Farms, Germantown, N. Y.) weighing 25- 
30 g as previously described (10). Peritoneal cells (6 ×  106) in minimum  essential alpha medium 
(a-MEM; Gibco Laboratories, Grand Island Biological Co., Grand Island, N. Y.) that contained 
10% fetal calf serum (FCS) were added to 35-mm diameter plastic culture dishes. After 2 h at 
37°C in 5% COz,  cultures were washed three times in a-MEM to remove nonadherent cells. 
Fresh medium plus 10% FCS (1 ml) that contained 0.5/~Ci/ml of [5,6,8,9,11,12,14,15-aH]20:4 
([aH]-20:4;  New England Nuclear, Boston, Mass.)  was then added to each dish, and the cells 
were incubated overnight (16 h). 
Corynebacterium parvum-elicited Macraphages.  C. paroum-elicited macrophages were obtained by 
injecting 1.4 mg formalin-killed C. parvum Coparvax; a gift of Dr. Tuttle, Burroughs Wellcome 
Co.,  Research Triangle Park,  N. C.)  intraperitoneally into each  mouse. Macrophages were 
harvested 11-t4 d later and cultured as described for resident cells. 
Preparation of Unopsonized Zymosan.  Zymosan was purchased from ICN, K & K Laboratories 
Inc., (Plainview, N. Y.), and stock solutions in t~-MEM were prepared as described (11). 
Preparation of Immune Complexes.  Horseradish peroxidase and rabbit antiserum against horse- 
radish  peroxidase  were  the  generous  gift  of Dr.  Ralph  M.  Steinman of The  Rockefeller 
University. Immune complexes were prepared at equivalence by incubating equal volumes of 
a solution of horseradish peroxidase (200 lag/ml in a-MEM) and antibody for 30 min at 37°C. 
The complexes were washed twice in calcium- and magnesium-free phosphate-buffered saline 
(PD) and suspended at a concentration equivalent to 20 #g/ml horseradish peroxidase (135/lg 
of total immune complex protein/dish) for addition to macrophage cultures. 
Production of LTC by Macrophage Cultures.  After the  16-h labeling period, cells were washed 
twice in a-MEM, and 1 ml ofserumless a-MEM that contained zymosan or immune complexes 
was added. After incubation for specified  time periods at 37°C in 5% COz,  the medium was 
removed and extracted for LTC. 
The cell monolayers were washed twice with PD, overlaid with 0.05% Triton X-100 (Rohm 
and Hass Co., Philadelphia, Pa.), and the dishes were scraped. Cell protein was determined by 
the method of Lowry et al. (12). Macrophages isolated from 6 ×  108 peritoneal cells contained 
~ 150/~g protein. 
Extraction of LTC.  Quantities given refer to 1 ml of medium. The medium was acidified to 
pH 3 with 10/~1 85% formic acid. Then 3.75 ml of chloroform:methanol 1:2 (vol:vol),  1.25 ml 
of chloroform, and 1.25 ml of water were added sequentially, with mixing after each addition. 
After centrifugation at  1,000 g for 15 min, the upper phase was removed and extracted with 6 
ml  of chloroform:ethanol  1:1  (vol:vol)  and  2  ml  of chloroform:ethanol 2:1  (vol:vol).  The 
chloroform-ethanol extracts were combined and concentrated under reduced pressure.  The 
extraction was performed at 4°C, and solvents contained 0.005% of the antioxidant butylated 
hydroxytoluene (Sigma Chemical Co., St. Louis, Mo.). 
Silicic Acid Column Chromatography of LTC.  The concentrated chloroform-ethanol extracts 
were dried under nitrogen, and the residues were dissolved in 0.1  ml of ethanol:water 80:20 
(vol:vol).  Samples were applied to columns (6 mm ×  10 cm) of activated silicic acid (Silicar 
CC-7; Mallinckrodt Inc., St. Louis, Mo.) packed in chloroform. Columns were eluted sequen- 
tially with 5 ml of chloroform, 15 ml of 5% methanol in chloroform, and 20 ml of methanol. All 
solvents contained 0.005%  butylated hydroxytoluene. Routinely, the solvent fractions were 
collected in glass scintillation vials, the first two solvents comprising fraction 1, and the third 
solvent comprising fraction 2. LTC eluted in fraction 2. Fractions of 2 ml were collected when 
elution profiles of standards and chloroform-ethanol extracts were monitored. Fractions were 
dried under a  stream of air, water (0.5 ml) was added, and radioactivity was  measured by 
liquid scintillation  counting in Hydrofluor (National Diagnostics, Inc., Advanced Applications 
Institute Inc., Sommerville, N. J.). 
Preparation of Radiolabeled LTC  Standard.  LTC  was  obtained  from  macrophage  cultures 
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solvent extraction, Sephadex G-25 column chromatography, and HPLC as described previously 
(9). 
Bioassay of LTC.  The bioassay for SRS activity was performed using an isolated guinea pig 
ileum in Tyrode's solution  in the presence of atropine (1 pM) and pyrilamine maleate (1 #M), 
by the method of Chakravarty (13). 1 U SRS activity was arbitrarily defined as that amount 
that produced a contraction equal in amplitude to 5 ng histamine. The second fractions from 
silieic acid columns were dried under reduced pressure  and dissolved in Tyrode's solution for 
testing.  FPL 55712 (Fisons Pharmaceuticals, Loughborough, England) was used to test inhibi- 
tion of SRS induced contractions (14). 
Assay of Prostaglandin E  (PGE)  Release.  Maerophages were isolated,  prelabeled with  [aH]- 
20:4, and challenged with zymosan as described  above. After the desired  incubation periods, 
the media were  removed and the prostaglandin  (PC)  extracted and  purified by silicie acid 
column chromatography as described  previously (15). PGE release was quantitated by radio- 
activity recovered in  the  2.5% methanol  in  chloroform fraction  from  the  columns,  and  is 
expressed as pmol of PGE/ffg of cell protein. 
Calculations.  The molar quantity of LTC obtained in radiolabeled samples was calculated 
using the specific activity of [all]-20:4 in the maerophage phospholipids (53.7 dpm/nmol). The 
determination of [aH]-20:4-specific activity was based on an uptake of 90% of the label added 
to the cultures,  and incorporation of 70% of the label into the phospholipid pool (15). 
Results 
Assay  of LTC  Synthesis.  In  our  earlier  work  (9),  we  showed  that  macrophages 
prelabeled with  [3H]-20:4 and stimulated with zymosan released radiolabeled  LTC 
into the culture medium. We further demonstrated that the amount of LTC calculated 
from the radiolabel content of purified preparations was in excellent agreement (80%) 
with  that estimated from amino acid analysis.  Radioactivity measurements of such 
samples, therefore, could be used to quantitate the amount of LTC released. To make 
such an assay method practical,  it was necessary to develop techniques  that would 
facilitate the processing of large numbers of samples. This problem was simplified in 
that  only  radiochemical  purity  of  LTC  was  required,  making  extensive  HPLC 
purifications unnecessary.  We therefore developed a  procedure for obtaining radio- 
chemically pure LTC as follows. 
Media  from macrophage cultures labeled with  [~H]-20:4, and subsequently chal- 
lenged with zymosan, were extracted for LTC. From our previous work, we knew that 
the  major radiolabeled  contaminant  of LTC in  the chloroform-ethanol  extracts of 
culture  media was PC.  Separation  of PG and  LTC was accomplished  by stepwise 
elution of the concentrated chloroform-ethanol extracts from silicic acid columns. Fig. 
1 shows the aH-elution profile from this column. Also shown are the elution profiles 
for [SH]-PGE~ and  [SH]-LTC standards.  Three peaks of radioactivity were obtained 
on chromatography of media extracts (Fig.  1 C). The first two of these peaks coeluted 
with PGE2, which was recovered in the chloroform, and 5% methanol in chloroform 
fractions (Fig. 1 A). The third peak from the chloroform-ethanol extracts was recovered 
in the methanol fraction and coeluted with the LTC standard  (Fig.  1 B). These data 
indicated that LTC could be separated from PG and other less polar 20:4 metabolites 
by this procedure. 
Reverse-phase HPLC was used to verify that the LTC in the methanol eluate from 
the  silicic  acid  columns  (fraction  2)  was  radiochemically  pure.  Fraction  2  was 
concentrated  and  applied  to  a  column  of Lichrosorb  C-8  (Altex  Scientific,  Inc., 
Berkeley, Calif.) routinely used for the purification of LTC standard. A single peak of 
radioactivity was obtained, which had a retention time (170 rain) identical with that C.  A.  ROUZER,  W.  A.  SCOTT,  A.  L.  HAMILL, AND Z.  A.  COHN  1239 
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FIG.  1.  3H-elution profiles of" (A) [3HI-PGFa and (B) [3HI-LTC standards, and (C) the chloroform- 
ethanol extract of macrophage culture medium. Macrophages in a  35-ram diameter culture dish 
were prelabeled for 16 h with [all]-20:4 and then challenged with zymosan (160 pg). After 1 h, the 
medium was  removed, extracted,  and  subjected  to  silicic  acid  chromatography as  described  in 
Materials and Methods. Standards were dissolved in ethanol:water 80:20 (vohvol) and applied to 
identical silicic acid columns. Fractions of 2 ml were collected, dried under air, and the radioactivity 
determined. 
of LTC standards  (Fig.  2). The column effluent was also monitored for the presence 
of compounds with free amino groups by reaction with fluorescamine (16,  17).  The 
aH  peak corresponded  to a  fluorescamine-positive  peak.  Other,  nonradioactive  flu- 
orescamine-positive  peaks were also present,  but  these  were well-resolved  from the 
LTC.  From  these  data,  we concluded  that  LTC  was  recovered  from  fraction  2  of 
silieic acid columns, and that this LTC was free of radiolabeled contaminants. 
The  recovery of the biological  activity of LTC  after silicic acid chromatography 
was also examined. For this purpose, HPLC-purified [aH]-LTC standard was dissolved 
in  a-MEM,  extracted,  and  subjected  to  silicic  acid  chromatography.  Recovery  of 
radioactivity was 50%  after the extraction step and 40%  after chromatography.  Fig. 
3 shows the results of bioassay of this LTC before and after treatment. Dose-response 
curves are presented for histamine and untreated LTC standard dissolved in a-MEM. 
The LTC caused a  half-maximal contraction of the ileum at a concentration of 5  X 1240  LEUKOTRIENE  C  PRODUCTION  BY  MACROPHAGES 
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FIo.  2.  HPLC elution profile of fraction 2  from silicic acid columns. Macropbages in a  35-mm 
dish were labeled  and  stimulated  with  zymosan as  in  Fig.  1.  The  medium  was  extracted  and 
chromatographed on silicic acid. The methanol eluate (fraction 2) was dried under reduced pressure, 
redissolved in HPLC starting buffer, and subjected to chromatography on a column of Lichrosorb 
C-8 as described previously (9). Elution profiles for aH (---) and relative fluorescence after reaction 
with fluorescamine (--) are shown. 
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Fie.  3.  Bioassay of LTC standard before and after extraction and silicic acid chromatography. 
[3HI-LTC standard was obtained from macrophages prelabeled with [3H]-20:4  and challenged with 
zymosan as described previously (9). Purified standard was dissolved in a-MEM (64,000  dpm/ml) 
and two samples (1  ml each) were extracted and chromatographed on silicic acid.  Bioassay was 
performed on untreated standard (O), and on fraction 2 from the silicic acid columns after drying 
and redissolving in Tyrode's solution (A). The dose-response curve for histamine is also shown for 
comparison ((3). 
10  -~°  M;  at  this  concentration  it  was  500  times  more  potent  than  histamine  on  a 
molar  basis.  Fig.  3  also shows a  dose-response  curve  for the  LTC  standard  recovered 
in  silicic acid  column  fraction  2  from  two  separate  extractions.  These  samples  gave C.  A.  ROUZER,  W. A.  SCOTT,  A.  L.  HAMILL, AND Z. A. COHN  1241 
responses identical to those of the untreated LTC, indicating that the recovered LTC 
had retained its full biological activity. 
From the above data we could draw the following conclusions. LTC can be partially 
purified  from  macrophage  culture  medium by  solvent  extraction  and  silicic acid 
chromatography. LTC treated in this way is recovered in 40% yield with full retention 
of  biological  activity.  Because  the  LTC  is  radiochemically pure,  the  amount  of 
radioactivity recovered in the methanol eluates from the silicic acid columns can be 
used as a  direct  measurement of the quantity of LTC in the sample. Furthermore, 
because the specific activity of [3H]-20:4 in the macrophage phospholipids is known 
(15),  the  radioactivity  recovered  can  be  related  to  the  molar  quantity of  LTC. 
Therefore, the use of these techniques forms the basis of an assay for LTC release by 
macrophages in vitro when the cells are prelabeled with [3H]-20:4 under the specified 
conditions. 
Kinetics of Release of LTC and Other 20:4 Metabolites after Zymosan Ingestion.  Fig.  4 
shows the time-course of total 20:4, PGE, and LTC release by macrophages prelabeled 
with [3H]-20:4 and challenged with zymosan. The release of PGE and LTC followed 
similar kinetics and both were comparable with that of 20:4 (total 3H). In each case, 
the levels of the metabolite increased linearly for 60 rain after the addition of zymosan, 
and  remained constant thereafter.  Compared  with  control cultures  (no  zymosan), 
exposure to zymosan promoted a 40-fold increase in LTC synthesis and a comparable 
increase  in  PGE  (15).  Bioaetivity measurements of the  amount  of released  LTC 
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FIG. 4.  Time-course  of LTC  release in response to zymosan. Macrophages were isolated and 
prelabeled with [~H]-20:4.  After the 16-h labeling period, the cells  were washed and challenged with 
160 leg zymosan. At the specified times, the medium was removed and an aliquot counted. The 
PGE or LTC was extracted and purified by silicic acid chromatography. A.  LTC release was 
calculated from fraction 2, corrected for a 40% recovery,  and is the mean + SD of triplicate cultures 
(0). LTC release is also shown for cultures not given zymosan (O). At selected time points, LTC in 
the medium from additional cultures was bioassayed for SRS activity (A). B. Release of total [aH]- 
20:4 was calculated directly from the disintegrations per minute recovered in the medium and is 
expressed as the mean of triplicate cultures (0).  PGE release was calculated from the radiolabel 
recovered in the 2.5% methanol in chloroform fraction from the columns, corrected for a  70% 
recovery, and is the mean of duplicate cultures (O). All release values are given in terms of pmol/ 
~g of cell protein. 1242  LEUKOTRIENE C  PRODUCTION  BY  MACROPHAGES 
(fraction 2 of the silicic acid columns) were in good agreement with those measured 
by radioactivity. 
LTC Production and Zymosan Concentration.  Macrophage  cultures  were  challenged 
with different doses of zymosan, and the amount of LTC released was assessed after 
90 min of incubation. The results of these experiments are presented in Fig. 5. LTC 
release was linear with zymosan dose up to 100 #g (coefficient of correlation =  0.98). 
Above this dose, progressively smaller increases in LTC release were obtained with 
increasing amounts of zymosan. Also shown in Fig. 5 are results from the bioassay of 
samples from fraction 2. These were in good agreement with the radioassay. Because 
previous studies indicated that cell viability was best maintained at doses of zymosan 
not exceeding 160 #g (W. A. Scott. Unpublished observations.), this dose was used for 
all subsequent experiments. 
Kinetics of L TC Release by C. parvum-Elicited Macrophages.  Macrophages were elicited 
by a single intraperitoneal dose of C. parvum and harvested after 11 d. These cells were 
cultured and prelabeled with [ZH]-20:4  by the same methods used for resident cells. 
Uptake of [3H]-20:4 was identical in the two macrophage populations, and C. parvum- 
elicited macrophages ingested zymosan to the same extent as did resident cells.  Fig. 
6 shows the kinetics of LTC release by C. parvum-elicited macrophages after a challenge 
dose of 160 #g of zymosan. Also shown is LTC release by resident macrophages at 60 
and  120 min. It is evident that, although the kinetics of release by C. parvum-elicited 
cells were similar to those of resident cells (compare with Fig. 4A), lower maximal 
levels of LTC synthesis were reached by the elicited cells (68 +  16 dpm of LTC/#g of 
cell protein) as compared with resident macrophages (156 _  30 dpm of LTC/#g of 
cell protein). 
Production of L TC by Macrophages Exposed to lmmune Complexes.  Fig.  7 illustrates the 
kinetics of production of LTC by resident  macrophages challenged with  insoluble 
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FIG..5.  Effect of zymosan concentration on LTC  release. Experimental details are the same as 
those in Fig. 4, except that zymosan was added in the specified doses,  and all cultures were incubated 
for 90 men. Values of radioactivity are the mean +  SD for triplicate cultures (O), and are expressed 
as dpm of LTC//*g of cell protein recovered in fraction 2. Values of bioactivity were obtained from 
dose-response determinations of individual samples in the ileum assay (0). C.  A.  ROUZER,  W. A. SCOTT,  A.  L.  HAMILL, AND Z.  A. COHN  1243 
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F1o. 6.  Time-course of LTC synthesis by C. parvum-elicited  macrophages in response to zymosan. 
Mice were injected intraperitoneally with C parvurn, and macrophages were harvested after 11-14 
d. Details of culture, labeling, and zymosan challenge of these cells are the same as in Fig. 4. Results 
given are the  mean  ±  SD  from  triplicate cultures  of C  pan,urn-elicited (Q)  and  resident  (O) 
macrophages. 
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FIC~. 7.  Time-course of LTC release by macrophages exposed to immune complexes. Experimental 
details are the same as in Fig. 4, except that macrophages were challenged with immune complexes 
(135/xg of immune complex protein/dish). Values are the mean ± SD from triplicate  determinations. 
immune complexes (135 #g of immune complex protein/dish). The kinetics of LTC 
production were similar to those obtained with zymosan; however, the maximal levels 
of LTC  attained were  lower  (compare with  Fig. 6).  Dose-response studies in which 
doses of up to  1,300/xg of immune complex protein/dish were added indicated that 
no further stimulation of LTC release could be achieved with these complexes. 
Quantities  of  LTC  Released  by  Mouse  Macrophages  under  Different  Experimental 
Conditions.  Results obtained  from  a  number  of experiments  indicated that  macro- 
phages  stimulated  with  zymosan  (160  #g)  released  -3-6  pmol  of LTC/#g  of cell 
protein  after  1-2  h  incubation.  This  estimate  was  derived  from  the  radiolabel 
recovered in fraction 2  from silicic acid columns, corrected for a  40%  recovery, and 
converted to pmol as described in Materials and Methods. The release of 3-6 pmol/ 1244  LEUKOTRIENE C  PRODUCTION  BY  MACROPHAGES 
/~g of cell protein corresponded to a bioactivity of 35-70 U/#g of cell protein. In most 
studies, the radioactivity recovered in fraction 2 comprised, on the average, 6-12% of 
the total aH released by the cells.  Correcting this value for a 40% recovery, it may be 
concluded  that  as  much  as  15-30%  of the  released  20:4  is  converted to  LTC  by 
resident cells under these conditions. 
C. parvum-elicited macrophages released -3 pmol of LTC//~g of cell protein when 
challenged with  zymosan  (160 gg).  This  represented  50%  of the  amount  of LTC 
released by resident  cells  in  parallel  cultures  (6  pmol  of LTC/#g of cell protein). 
Stimulation of resident cells with immune complexes led to a maximal release of 1.3 
pmol of LTC/gg of cell protein, -20% of that obtained with zymosan. 
Discussion 
Progress in the study of SRS has been slow as a  result of a  number of technical 
problems  that  have  existed  in  the  past.  The  bioassay  for  SRS,  although  highly 
sensitive, lacks specificity, and conveys no information concerning the nature of the 
substance(s)  being tested. Lack of complete information concerning the structure of 
the  molecule impeded work on  its  biochemistry.  Finally,  no  purified, normal  cell 
population  was  available  that  could  be  shown  to  release  SRS  in  response  to  a 
physiologically relevant stimulus in  vitro. This prevented the detailed study of the 
regulation of SRS release. The recent chemical characterization of LTC and LTD (5, 
6)  has provided important information necessary to overcome these problems; how- 
ever, much remains to be done to elucidate the cell(s) of  origin, control of biosynthesis, 
and metabolism of these compounds. 
The finding that  mouse peritoneal  macrophages  release  LTC  in  response  to an 
inflammatory stimulus was consistent with other work that implied that the mast cell 
may  not  be  the  cell  of origin  of SRS  as  was  originally  thought  (18-21).  The 
macrophage offered obvious advantages for the detailed study of the release of LTC 
because purified cell populations were readily available, and because methods for the 
labeling of maerophage phospholipid with [SH]-20:4 had already been developed for 
the study of PG production (15).  Furthermore, a simple method for the extraction of 
LTC from macrophage culture medium had been devised, allowing the recovery of 
the compound under very mild conditions (9). 
We took advantage of the above available techniques to devise the radiochemical 
assay for the release of LTC from mouse peritoneal macrophages described in this 
paper. Using the combination of solvent extraction and silicic acid chromatography, 
radiochemically pure LTC was obtained from culture medium in a  40% yield with 
full  retention of biological activity.  The results obtained  from assay of radiolabel 
recovered as LTC were in good agreement with those obtained from bioassay. The 
radioassay offered several advantages over the bioassay, however. Large numbers of 
samples could be processed rapidly, in large part because of the step-wise nature of 
separations on silicic acid columns. The inherent variability in sensitivity from one 
ileum preparation to another was no longer of concern, and the problems presented 
by  substances  that  interfere  with  the  bioassay  (PG,  histamine,  serotonin)  were 
eliminated. 
We used the radioassay to study some of the parameters affecting LTC synthesis by 
macrophages in vitro. Results from these experiments indicated that  the kinetics of 
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very similar  to  results  obtained  for  PG  and  total  20:4  release.  In  both  cases,  the 
kinetics of release of the 20:4 metabolites closely followed those of phagocytosis of 
zymosan obtained previously (15), and increasing amounts of the metabolites were 
synthesized in response to increasing quantities of zymosan ingested. These findings 
are consistent with the hypothesis that a phagocytic stimulus triggers 20:4 release by 
an inducible phospholipase, and that the 20:4 is then metabolized by cyclooxygenase 
(giving PG) and lipoxygenase (yielding hydroxyeicosatetraenoic acids and LTC). 
C. parvum is  well  recognized as  a  nonspecific stimulator of the  immune  system. 
Peritoneal macrophages obtained from mice injected with C. parvum exhibit increased 
tumoricidal  and  antimicrobial  activities  in  vitro  (22,  23).  Comparisons  of LTC 
released by these cells and resident cells after an in vitro challenge with a phagocytic 
stimulus  may  provide  useful  information  as  to  the  capacity  of macrophages  to 
synthesize LTC in chronic and acute inflammatory sites.  Our findings indicate that 
macrophages obtained after a single intraperitoneal injection of C. parvum release 50% 
less  LTC  than  resident cells.  Similarly, Humes  et  al.  (24)  reported  decreased  PG 
release by  C. parvum-elicited macrophages.  These findings  together would  seem  to 
indicate that 20:4 metabolism by C. parvum-elicited maerophages is different from that 
of resident cells.  Further work is being conducted in this laboratory to better define 
the nature of these effects. 
Macrophages are known to recognize and  ingest immune complexes via their Fc 
receptor for IgG.  Because maerophages are exposed to immune complexes in their 
role as inflammatory cells, it is of interest to know if these particles can serve as a 
trigger for LTC release. We have shown  that  macrophages  do synthesize LTC in 
response to a  challenge with immune complexes, although a  lower maximal release 
was  obtained when  the cells were stimulated  with  zymosan.  Total  20:4  release in 
response  to  immune  complexes was  also  lower than  that  obtained  from  zymosan 
challenge. It is not known why immune complexes appear to be a less potent trigger 
of 20:4 release than zymosan. Factors such as size and class of antibody used in their 
formation may influence the efficiency  of immune complexes to stimulate 20:4 release. 
In our previous work, we estimated that the release of LTC by resident macrophages 
after challenge with zymosan (160 #g) was 2.1  pmol/#g of cell protein, comprising 
10-15%  of the  total  20:4  released  and  possessing  a  bioaetivity of 24  U/Ixg  of cell 
protein (9). In the present studies, higher values of LTC released were obtained (3-6 
pmol/#g of cell protein, 15-30% of the 20:4 released, and 35-70 U//~g of cell protein). 
These differences may be attributed to different lots of zymosan and their ability to 
stimulate 20:4 metabolism. The values presented here better reflect the capacity of 
the macrophage for LTC release. 
That  mouse  peritoneal  macrophages  release  LTC  in  response  to  inflammatory 
stimuli cannot be disputed. This is a clear example of the synthesis of an SRS by a 
purified normal cell population in response to an immunologically relevant stimulus 
in which the product has been chemically characterized and quantitated. Information 
of this type is  vital to the understanding of the physiologic and pathologic role of 
SRS. The findings presented here raise some interesting questions. What role, if any, 
does the macrophage play in the generation of SRS in an immediate hypersensitivity 
reaction? If the macrophage is involved, what is the trigger that stimulates its release 
of leukotriene? What  is  the  physiological significance of leukotriene release in  the 
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chronic inflammatory reactions where the involvement of macrophages is well known? 
It  is  clear  that  our  present  understanding  of the  biochemistry,  immunology,  and 
physiology  of  SRS  must  be  broadened  extensively  to  accommodate  the  rapidly 
growing knowledge of the leukotrienes. 
Summary 
A  method  for the  radiochemical  assay of LTC  production  by mouse peritoneal 
macrophages  in  vitro  is  presented.  The  method  involves labeling  macrophages  in 
culture with [5,6,8,9,11,12,14,15-~H]20:4  followed by stimulation of arachidonic acid 
(20:4) release under the experimental conditions desired. Radiolabeled leukotriene C 
(LTC)  is recovered from the culture medium by extraction and silicic acid chroma- 
tography in 40% yield with full retention of biological activity. Because this LTC is 
radiochemically pure, the quantity of LTC release may be estimated from the amount 
of radioactivity in the sample. 
Use of the radioassay to study parameters affecting LTC synthesis by macrophages 
indicated that the time course of LTC synthesis and its relationship to the dose of a 
phagocytic  stimulus  (zymosan)  were  very  similar  to  those  of prostaglandin  (PG) 
release.  LTC  release  was  also  similar  to  that  of PG  in  that  lower  levels  of both 
metabolites were  produced  by  Co~ynebacterium parvum-elicited  macrophages  than  by 
resident  cells.  Finally,  LTC release was stimulated  in  response to a  challenge  with 
antigen-antibody complexes, but lower maximal levels were attained than those with 
zymosan. 
The  data  presented  here  are  consistent  with  the  hypothesis  that  challenge  of 
macrophages with a  phagocytic stimulus leads to the release of 20:4 by an inducible 
phospholipase. Cyclooxygenase and lipoxygenase then compete for the released 20:4, 
leading to the production of PG, hydroxyeicosatetraenoic acids, and LTC. 
Received  for publication 10 July t 980. 
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